Hear from Dr. Jay K. Varma, SIGA’s Chief Medical Officer, to learn more about the National Institute of Allergy and Infectious Diseases (NIAID) topline results from a preliminary analysis of the PALM 007 (Tecovirimat for Treatment of Monkeypox Virus) clinical trial (NCT05559099).